Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

NCT03693339 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Lung Cancer Metastatic
MET Gene Mutation

Interventions

DRUG: Capmatinib

Sponsor

Asan Medical Center